Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Anesthesia adjunct (induction and maintenance),Analgesia during anesthesia (e.g., for surgery, mechanical ventilation),Management of acute pain (e.g., procedural sedation),Treatment of breakthrough pain in opioid-tolerant patients (via transmucosal formulations),Patient-controlled analgesia (PCA),Epidural or intrathecal analgesia (off-label),Prehospital analgesia for trauma (off-label)
Mild to moderate pain,Fever
25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is 3–12 hours (mean ~7 hours) in adults; prolonged in elderly, hepatic impairment, or with continuous infusion due to context-sensitive half-life.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Fentanyl undergoes extensive hepatic metabolism primarily via CYP3A4 N-dealkylation to norfentanyl (inactive) and other minor metabolites. Approximately 75% of the dose is excreted as metabolites in urine (primarily norfentanyl) and about 9% in feces. Less than 7% is excreted unchanged in urine. The terminal half-life is 3–12 hours, influenced by factors such as hepatic function and age.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily hepatic metabolism to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for ~75% of the dose (10% unchanged), with ~9% excreted in feces.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
~80–85% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Vd: 3–8 L/kg (mean ~4 L/kg), indicating extensive tissue distribution and high lipophilicity.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Transdermal: ~92%; Transmucosal (buccal): ~50%; Oral transmucosal lozenge: ~33%; Intranasal: ~50–70%; Oral (swallowed): very low due to first-pass metabolism (~30% but variable).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR 30-50: use with caution, consider dose reduction by 25-50%; GFR <30: avoid or initiate at 50% of usual dose and titrate slowly; anuric patients: significant accumulation, consider alternative.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or use with extreme caution, reduce dose by 75%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
IV: 1-2 mcg/kg every 2-4 hours; transdermal: not recommended in opioid-naïve children <2 years, start at 12.5 mcg/h if >50 kg; transmucosal: 5-15 mcg/kg as single dose.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at 50% of usual adult dose, titrate cautiously by 25% increments; avoid transdermal in opioid-naïve elderly; monitor for respiratory depression and cognitive impairment.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: RISK OF RESPIRATORY DEPRESSION, ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISK OF MEDICATION ERRORS (especially with transmucosal formulations).
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Life-threatening respiratory depression: risk dose-dependent; monitor respiratory function, especially during initiation and dose escalation.,Addiction, abuse, and misuse: can occur even at recommended doses; screen patients for risk.,Neonatal opioid withdrawal syndrome: prolonged use during pregnancy can result in withdrawal in the newborn.,Interaction with CNS depressants: concomitant use with benzodiazepines or alcohol may cause profound sedation, respiratory depression, coma, and death.,Accidental exposure: especially with transdermal patches; can be fatal.,Risks from use in patients with head injury or increased intracranial pressure: may obscure neurological signs.,Severe hypotension: in patients with compromised blood volume or concomitant use of drugs that depress blood pressure.,Bradycardia and heart block: use with caution in patients with bradyarrhythmias.,Seizures: may exacerbate seizure disorders.,Serotonin syndrome: when used with serotonergic drugs.,Adrenal insufficiency: with prolonged use.,Severe injection site reactions: with injectable formulations.,Risk of medication errors: especially with different formulations (e.g., transdermal vs. transmucosal).
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to fentanyl or any component of the formulation,Significant respiratory depression (in unmonitored settings or without resuscitative equipment),Acute or severe bronchial asthma,Paralytic ileus (known or suspected),Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy,Use in opioid-naive patients for transmucosal immediate-release fentanyl (due to risk of fatal respiratory depression),Acute abdomen (relative contraindication; may obscure diagnosis)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit and grapefruit juice as they can increase fentanyl levels via CYP3A4 inhibition. No other significant food interactions. Maintain adequate hydration to prevent constipation.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
First trimester: Limited data; no major malformations reported. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome. High doses near term may cause respiratory depression and neonatal abstinence syndrome.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Fentanyl is excreted into breast milk. Milk-to-plasma ratio is approximately 0.4. Avoid use in lactating women who are poor metabolizers or receive high doses due to risk of infant sedation and respiratory depression.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Clearance of fentanyl is increased during pregnancy, particularly in the third trimester. Dose adjustments may be required; consider increasing dose or frequency. Monitor for efficacy and adjust as needed.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Fentanyl is 50-100 times more potent than morphine. Due to high lipophilicity, onset of analgesia is rapid (within 30 seconds IV) but duration is short. Avoid bolus dosing in opioid-naive patients due to risk of chest wall rigidity. Transdermal patches are not indicated for acute pain due to slow onset and prolonged effect. Monitor for respiratory depression, especially in elderly and those with sleep apnea. Tolerance and physical dependence develop with chronic use. Naloxone is the reversal agent.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Do not drive or operate heavy machinery until you know how fentanyl affects you.,Take exactly as prescribed; do not increase dose or frequency without doctor approval.,Avoid alcohol and other CNS depressants as they increase risk of severe drowsiness and respiratory depression.,Store fentanyl patches and other formulations safely out of reach of children and pets; used patches should be folded and flushed down toilet.,Do not share this medication with others; it can cause fatal overdose.,Seek emergency medical help if you experience slow/shallow breathing, extreme drowsiness, or difficulty waking up.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL vs ACEPHEN, answered by our medical review team.
FENTANYL is a Opioid Agonist that works by Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL is: 25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENTANYL and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENTANYL is classified as Category D/X. First trimester: Limited data; no major malformations reported. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome. High doses near t. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.